


http://www.pharmexec.com/meeting-unmet-medical-needs-disparity-dilemma-0


http://dx.doi.org/10.1377/hlthaff.2014.1047


http://dx.doi.org/10.1377/hlthaff.2014.1023

Kaitin KI, editor. Anticipating and managing a changing site landscape.

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
[http://dx.doi.org/10.2217/bmm.14.84](http://dx.doi.org/10.2217/bmm.14.84)

[http://dx.doi.org/10.2217/bmm.14.66](http://dx.doi.org/10.2217/bmm.14.66)


Stergiopoulos S, Surgeon L. The facilitated clinical trial protocol review: is the theory being put into good practice? *Chimica Oggi [Chemistry Today]*. 2014;32(6):52-56 [RS 3439]  

Kaitin KI, editor. CNS drugs take longer to develop, have lower success rates, than other drugs. *Tufts Center for the Study of Drug Development Impact Report*. 2014 Nov/Dec;16(6)** [RS 3438]

[http://dx.doi.org/10.1016/j.clinthera.2014.09.008](http://dx.doi.org/10.1016/j.clinthera.2014.09.008)


http://dx.doi.org/10.1016/j.clinthera.2014.09.007

Cohen JP. Patient access to orphan drugs faces new set of challenges. *Formulary*. Online publish date: September 15, 2014. [RS 3433]


http://dx.doi.org/10.5639/gabij.2014.0303.028


http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=845307&page_ID=1&sk=&date=

http://dx.doi.org/10.1016/j.clinthera.2014.05.004

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Getz KA. Q&A with Jean Burns: Insights from a study volunteer. *Applied Clinical Trials Online*. Online publish date: May 28, 2014. [RS 3422]


http://dx.doi.org/10.3390/ijerph110505069

http://dx.doi.org/10.1002/9781118783344.ch1


Getz KA. Coming to terms with interrupted drug development programs. *Applied Clinical Trials*. 2014;23(4/5):22-23. [RS 3417b]

http://dx.doi.org/10.1038/nrd4325

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/clpt.2014.14


http://www.manhattan-institute.org/html/fda_07.htm#.U1_t61dUinw


http://csdd.tufts.edu/reports/ebooks


http://dx.doi.org/10.3390/jpm4020163

http://dx.doi.org/10.1177/2168479014525957


Milne C-P, Davis J. The Pediatric studies initiative: after 15 years have we reached the limits of the law? *Clinical Therapeutics.* 2014;36(2):156-162. [RS 3407]

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Milne CP. Prospects for rapid advances in the development of new medicines for special medical needs. *Clinical Pharmacology & Therapeutics*. 2014;95(1):98-109. [RS 3401b] [http://dx.doi.org/10.1038/clpt.2013.155](http://dx.doi.org/10.1038/clpt.2013.155)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://cognoscenti.wbur.org/2013/12/18/series-prescription-drug-pipeline-sidney-wolfe-kenneth-kaitin


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=828039


http://dx.doi.org/10.1586/17512433.2013.841539

Getz KA. Leveraging pharmacists as a channel to raise clinical research literacy among patient communities. Applied Clinical Trials. 2013;22(10):30-33. [RS 3337]


http://www.scripintelligence.com/home/Flexible-global-more-adaptive-clinical-trials-2.0-346528

http://dx.doi.org/10.1038/clpt.2013.129

http://dx.doi.org/10.1038/clpt.2013.129


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Articles/Lifting-Up-a-Fragmented-Study-Conduct-Landscape/ArticleStandard/Article/detail/820680


http://dx.doi.org/10.1517/21678707.2013.819289

http://dx.doi.org/10.1038/clpt.2013.117


**This publication is for sale at our website**  
http://csdd.tufts.edu/reports


http://dx.doi.org/10.1177/2168479013494386

Milne CP. On the partnering path from the US to Asia: how far, how fast for university-industry collaborations? Pharma Focus Asia. 2013;(18):40-45. [RS 3323]
http://www.pharmafocusasia.com/strategy/partnering-path-us-asia


http://dx.doi.org/10.1016/j.clinthera.2013.04.004

http://www.panstanford.com/books/9789814316996.html


http://images2.advanstar.com/ PixelMags/pharma-executive/digitaledition/05-2013.html#38

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

http://dx.doi.org/10.3111/13696998.2013.793693

Getz KA. Building clinical trial awareness for patients: why not try the pharmacist? *Pharmaceutical Executive*. Published March 1, 2013 [web document] [RS 3315]

Cohen JP. Think twice about how we let overseas use of Plan B guide us [letter to the editor]. *The Boston Globe*. April 21, 2013:K8. [RS 3314]


http://dx.doi.org/10.1377/hlthaff.2012.0707

http://dx.doi.org/10.1016/j.clinthera.2012.12.018

http://dx.doi.org/10.1016/j.cct.2013.02.007

http://dx.doi.org/10.1177/2168479013478953


**This publication is for sale at our website http://csdd.tufts.edu/reports**
Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin KI. Quantifying the magnitude and cost of collecting extraneous protocol data. *American Journal of Therapeutics*. 2013. [Published Ahead-of-Print; Last Updated: April 9, 2013] [RS 3307]
http://dx.doi.org/10.1097/MJT.0b013e31826fc4aa


http://dx.doi.org/10.1097/MJT.0b013e318269198f


Kaitin KI, editor. 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. *Tufts Center for the Study of Drug Development Impact Report*. 2013 Jan/Feb;15(1)** [RS 3302]

http://dx.doi.org/10.1177/2168479012469947


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1016/j.anai.2012.11.014

http://dx.doi.org/10.1634/theoncologist.2012-0235


Nov/Dec;14(6)** [RS 3235]

http://dx.doi.org/10.1586/ecp.12.44

http://dx.doi.org/10.1007/s12031-012-9803-8

Oct;7(4)** [RS 3233]

http://dx.doi.org/10.1097/MJT.0b013e318262316f

http://www.topra.org/regulatory-rapporteur-oct-2012

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1007/BF03262374


Kaitin KI. Translational research and the evolving landscape for biomedical innovation. *Journal of Investigative Medicine*. 2012;60(7):995-998 [RS 3228]  
http://dx.doi.org/10.231/JIM.0b013e318268694f

http://dx.doi.org/10.1586/erp.12.25


http://dx.doi.org/10.1177/0092861512453040


http://dx.doi.org/10.1038/clpt.2012.87


http://www.pharmafocusasia.com/research_development/application-Biopharmaceutics-Classification-System-Drug-Development.htm


http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Feature+Article/Outsourcing-Landscape/ArticleStandard/Article/detail/772232


http://dx.doi.org/10.1016/j.drudis.2012.04.006

http://dx.doi.org/10.4161/mabs.19931


**This publication is for sale at our website** http://csdd.tufts.edu/reports


**This publication is for sale at our website http://csdd.tufts.edu/reports


Kaitin KI. Creating innovation nodes to meet unmet medical needs. *Pharmaceutical Technology.* 2011;35(12):27 [RS 3132]

Getz KA. Transforming legacy R&D through open innovation. *ACRP Monitor.* 2011;25(7):17-21 [RS 3131b]

http://dx.doi.org/10.1089/pop.2011.0020


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Wilson A, Cohen J. Patient access to new cancer drugs in the United States and Australia. *Value in Health*. 2011;14:944-952 [RS 3127] [http://dx.doi.org/10.1016/j.jval.2011.05.004](http://dx.doi.org/10.1016/j.jval.2011.05.004)

Beck A, Reichert JM. Therapeutic fc-fusion proteins and peptides as successful alternatives to antibodies. *MAbs*. 2011;3(5):415-416 [RS 3126c] [http://dx.doi.org/10.4161/mabs.3.5.17334](http://dx.doi.org/10.4161/mabs.3.5.17334)


Cohen J. Dearth of clinically useful diagnostics limits growth of personalized medicine. *Expert Review of Clinical Pharmacology*. 2011;4(5):527-529 [3125b] [http://dx.doi.org/10.1586/ecp.11.45](http://dx.doi.org/10.1586/ecp.11.45)


Kaitin KI, Milne C-P. A dearth of new meds. *Scientific American*. 2011;305(2):16 [RS 3123] [http://dx.doi.org/10.1038/scientificamerican0811-16](http://dx.doi.org/10.1038/scientificamerican0811-16)

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.4161/mabs.3.4.16589


http://dx.doi.org/10.1177/009286151104500403

http://dx.doi.org/10.1177/009286151104500406


Kaitin KI. 21st Century innovation: academic-industry partnerships are increasingly important in biopharmaceutical innovation. *Pharmaceutical Technology.* 2011;35(6):32 [RS 3119]
http://pharmtech.findpharma.com/pharmtech/article/articleDetail.jsp?id=724982&sk=&date=&&pageID=1

http://www.emaud.org/Doc/Market_Access_Newsletter_EMAUD_June%202011.pdf


Reichert JM. The amazing, multipurpose antibody. *mAbs.* 2011;3(3):221-222. [RS 3116b]
http://dx.doi.org/10.4161/mabs.3.3.15625

http://dx.doi.org/10.2217/pme.11.38

**This publication is for sale at our website http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1177/009286151104500316

http://dx.doi.org/10.1177/009286151104500307

http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=719542&sk=9270beba3a37ef7e37f3fa5477ea1cf9%22


Kaitin KI, editor. New or modified indications for existing drugs have steadily increased in the U.S. *Tufts Center for the Study of Drug Development Impact Report*. 2011 Mar/Apr;13(2)** [RS 3111]

http://dx.doi.org/10.4161/mabs.3.2.14788

http://dx.doi.org/10.1177/009286151104500203

Getz KA. Low hanging fruit in the fight against inefficiency. *Applied Clinical Trials*. 2011;20(3):30-32 [RS 3109]
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Articles/Low-Hanging-Fruit-in-the-Fight-Against-Inefficiency/ArticleStandard/Article/detail/711311?contextCategoryId=37194

http://dx.doi.org/10.1038/clpt.2010.286


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
Getz KA. The ultimate act of appreciation of study volunteers. *Focus*. 2011;3:8-12 [RS 3106b]


[http://dx.doi.org/10.4161/mabs.3.1.13895](http://dx.doi.org/10.4161/mabs.3.1.13895)


[http://dx.doi.org/10.1038/nrd3296](http://dx.doi.org/10.1038/nrd3296)


[http://dx.doi.org/10.1177/009286151104500106](http://dx.doi.org/10.1177/009286151104500106)


[http://dx.doi.org/10.4161/mabs.2.6.13603](http://dx.doi.org/10.4161/mabs.2.6.13603)

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/clpt.2010.167

http://dx.doi.org/10.1038/nbt1110-1160

Getz KA. Hurry up and wait, pharma puts the brakes on strategic outsourcing partnering. Inside Outsourcing. 2010 Nov;10-16 [RS 3026b]
http://www.nxtbook.com/nxtbooks/advanstar/insideoutsourcing_201011/#/12

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=693552


Getz KA. Providing results to volunteers. Applied Clinical Trials. 2010;19(10):52-59 [RS 3023b]

Getz KA. Ominous clouds over outsourcing. Applied Clinical Trials. 2010;19(9):28-30 [RS 3023]
http://license.icopyright.net/rights/tag.act?tag=3.7442%3ficx_id=686210

http://dx.doi.org/10.1038/nrd3229

RS 3021 Vernon JA, Golec JH, DiMasi JA. Drug development costs when financial risk is measured using the Fama-French three-factor model. Health Economics. 2010;19(8):1002-1005
http://dx.doi.org/10.1002/hec.1538

**This publication is for sale at our website  http://csdd.tufts.edu/reports

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=673673&sk=&date=&pageID=3


RS 3016d  Getz KA. Engaging pharmacists in research education. *Applied Clinical Trials.* 2010;19(7):30-32
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=678141

http://dx.doi.org/10.1038/clpt.2010.86

http://dx.doi.org/10.4161/mabs.12369

http://dx.doi.org/10.1093/jncli/djq246


http://dx.doi.org/10.1371/journal.pone.0010610

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

RS 3012  Getz K. FIPNet: Pharma’s new, sexy, but not yet ready for print-time model. *Applied Clinical Trials.* 2009;Suppl:10-12,14,16


Author manuscript; available in PMC 2011 August 4. PMCID: PMC3150117

RS 3010b  Getz KA. Conversations with study volunteers. *Applied Clinical Trials.* 2010;19(5):32-34
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/Conversations-With-Study-Volunteers/ArticleStandard/Article/detail/668513


RS 3009  Getz KA. Sizing up the clinical research market. *Applied Clinical Trials.* 2010;19(3):32-34
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=660749

RS 3008  Getz KA. With clinical data, less is more. *Applied Clinical Trials.* 2010;19(1):28-30
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/With-Clinical-Data-Less-is-More/ArticleStandard/Article/detail/652123

http://dx.doi.org/10.1093/protein/gzq018

RS 3007b  Getz KA. Understanding clinical trials: Appreciating medical heroes. *Media Planet.* 2010 Apr


http://dx.doi.org/10.4161/mabs.2.2.11320

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1097/MJT.0b013e3181ca7f10


http://dx.doi.org/10.1038/clpt.2009.293

http://dx.doi.org/10.1038/clpt.2009.295

RS 3002c Reichert JM. mAb therapeutic products and risk management. MAbs. 2010;2(1):1-2
http://dx.doi.org/10.4161/mabs.2.1.10628

RS 3002b Reichert JM. Antibodies to watch in 2010. MAbs. 2010;2(1):84-100;
http://dx.doi.org/10.4161/mabs.2.1.10786


RS 2934  Getz KA Vogel JR. Successful outsourcing: tracking global CRO usage. Applied Clinical Trials Online. 2009 Aug 17

**This publication is for sale at our website  http://csdd.tufts.edu/reports
RS 2933  Milne C-P. Can translational medicine bring us out of the R&D wilderness?  
*Personalized Medicine.* 2009;6(5):543-553  
http://dx.doi.org/10.2217/pme.09.40

RS 2932  Getz KA. Is an investigative site shake-out imminent?  
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/CRO%2FSponsor/
/Is-an-Investigative-Site-Shake-Out-Imminent/ArticleStandard/Article/detail/640464


RS 2930  Getz KA. Assessing the downstream impact of protocol design complexity.  
*Touch Briefings.* 2009:93-5

RS 2929  Kaitin KI. The changing landscape of drug development.  
*Mass High Tech.* 2009 Dec;27(43):29

RS 2928  Niezen MGH, de Bont A, Busschbach JJV, Cohen JP, Stolk EA. Finding legitimacy for the role of budget impact in drug reimbursement decisions.  
http://dx.doi.org/10.1017/S0266462309090072

*IDrugs.* 2009;12(12):779-784

RS 2926  Milne C-P Kaitin KI. Translational medicine: an engine of change for bringing new technology to community health.  
http://dx.doi.org/10.1126/scitranslmed.3000222

RS 2925  Cohen JP Bridges JFP. Assessing comparative effectiveness research in the US.  
http://dx.doi.org/10.1007/BF03256155

RS 2924  Kaitin KI, editor. Drug approvals for neglected diseases increased along with more R&D funding.  

RS 2923b  Reichert JM. Letter from the editor.  
http://dx.doi.org/10.4161/mabs.1.6.10059

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS2921b  Getz KA.  Into the aftermath of M&A.  *Applied Clinical Trials.* 2009;18(9)  


http://dx.doi.org/10.4161/mabs.1.5.9675

http://dx.doi.org/10.4161/mabs.1.4.9031


http://dx.doi.org/10.1177/009286150904300415

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://www.fldli.org/resources/resources-order-box-detail-view/off-label-use-reimbursement

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=609455


http://dx.doi.org/10.4161/mabs.1.4.9076


http://dx.doi.org/10.4161/mabs.1.1.7645


http://dx.doi.org/10.4161/mabs.1.3.8590


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

Reichert JM Nelson AL. Development trends for therapeutic antibody fragments. *Nature Biotechnology*. 2009;27(4):331-7 [http://dx.doi.org/10.1038/nbt0409-331](http://dx.doi.org/10.1038/nbt0409-331)


**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
http://dx.doi.org/10.2174/1874143600802010089

http://www.merckmanuals.com/home/special_subjects/the_science_of_medicine_and_clinical_trials/the_science_of_medicine.html

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/article/articleDetail.jsp?id=574844

http://dx.doi.org/10.2174/138920108786786358

http://dx.doi.org/10.4161/mabs.1.1.7646


RS2833b Getz KA. Should physicians enroll their own patients into clinical trials? *ACRP Monitor.* 2008 Dec;22(7):34-38

RS 2833 Kaitin KI. Offshoring cost effective clinical research. *Pharma Focus Asia.* 2008; (9):55-6
http://www.pharmafocusasia.com/clinical_trials/offshoring_cost_effective_clinical_research.htm

http://dx.doi.org/10.1504/IJBT.2008.021307

RS 2831 Milne C-P Bruss JB. The economics of pediatric formulation development for off-patent drugs. *Clinical Therapeutics.* 2008;30(11):2133-45
http://dx.doi.org/10.1016/j.clinthera.2008.11.019

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/nrd2733

http://dx.doi.org/10.1002/9780471462422.eoct382


http://dx.doi.org/10.1097/MJT.0b013e31816b9027


http://www.washingtonpost.com/wp-dyn/content/article/2008/09/26/AR2008092603126_pf.html


RS 2825b  Getz KA.  Getting to the heart of public distrust.  *Applied Clinical Trials*.  2008; 17(9):38-42


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


Getz KA. Is investigative site feasibility feasible? *Applied Clinical Trials.* 2008;17(7):36-38
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/Is-Investigative-Site-Feasibility-Feasible/ArticleStandard/Article/detail/527735

http://www.contractpharma.com/articles/2008/06/clinical-research-outsourcing

Zycher B, DiMasi JA, Milne C-P. *The truth about drug innovation: thirty-five summary case histories on private sector contributions to pharmaceutical science.* Manhattan Institute Center for Medical Progress. 2008;(6).
http://www.manhattan-institute.org/html/mpr_06.htm

Getz KA. First things first: patient recruitment. *Scrip.* 2008;371(6)

http://dx.doi.org/10.1002/9780471462422.eoct336


http://dx.doi.org/10.1215/03616878-2007-054

http://dx.doi.org/10.1215/03616878-2007-063

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 2815  Getz KA. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update.* 2008;Apr:4:5-6


http://dx.doi.org/10.1586/14737167.8.2.133


RS 2811  Getz KA. The heavy burden of protocol design. *Applied Clinical Trials.* 2008;17(5):38-40  

RS 2810  Getz KA. Tackling racial disparities in research. *Applied Clinical Trials.* 2008;17(1):40-42  

RS 2809  Getz KA. In search of efficiency between trial phases. *Applied Clinical Trials.* 2008;17(3):35-38  
http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Efficiency-Between-Trial-Phases/ArticleStandard/Article/detail/500433?contextCategoryId=37194

http://dx.doi.org/10.1097/MJT.0b013e31815fa75a


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1177/009286150804200108 |
http://dx.doi.org/10.1016/j.drudis.2007.09.003 |
http://dx.doi.org/10.1097/MJT.0b013e31815f9e52 |
http://dx.doi.org/10.1038/sj.clpt.6100462 |
| RS 2729 | Getz KA. In search of informed consent improvement. *Applied Clinical Trials*. 2007;16(11):42-45  
http://www.actmagazine.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Informed-Consent-Improvement/ArticleStandard/Article/detail/468090 |
| RS 2728 | DiMasi JA, Grabowski HG. Should the patent system for new medicines be abolished? *Clinical Pharmacology & Therapeutics*. 2007;82(5):488-90  
http://dx.doi.org/10.1038/sj.clpt.6100393 |
| RS 2727 | Cohen JP. CEA is not a price control (letter). *Health Affairs*. 2007;26(5):1505  
http://dx.doi.org/10.1377/hlthaff.26.5.1505 |
http://dx.doi.org/10.1108/17506120710818229 |

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1007/s10198-006-0028-z


RS 2723  Getz KA. Global clinical trials activity in the details. *Applied Clinical Trials.* 2007;16(9):42-44  

http://dx.doi.org/10.2165/00019053-200725090-00002

RS 2721  Kaitin KI, editor. Despite more cancer drugs in R&D, overall U.S. approval rate is 8%. *Tufts Center for the Study of Drug Development Impact Report.* 2007 Sep/Oct;9(5)**

http://dx.doi.org/10.1007/s10198-007-0055-4

http://dx.doi.org/10.1002/mde.1360

http://dx.doi.org/10.1002/mde.1341

RS 2717  Getz KA. CRA: jack of all trades. *Applied Clinical Trials.* 2007;16(7):36-38  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=439804


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
| RS 2713 | Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. *Nature Reviews Drug Discovery.* 2007;6(5):349-56 [http://dx.doi.org/10.1038/nrd2241](http://dx.doi.org/10.1038/nrd2241) |

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.2165/00124363-200620050-00003

RS 2704  Getz KA. Drowning in the sea of regulatory compliance. *Applied Clinical Trials.* 2007;16(2):32-34  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621

http://dx.doi.org/10.2165/00063030-200721010-00001

http://dx.doi.org/10.1200/JCO.2006.09.0803


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=392454

http://www.the-scientist.com/?articles.view/articleNo/24559/title/Just-Another-Day-at-the-Office-/  

RS 2624b  Cohen J  Cairns C  Paquette C  Faden L. Comparing patient access to pharmaceuticals in the UK and US. *Applied Health Economics and Health Policy.* 2006;5(3):177-87  
http://dx.doi.org/10.2165/00148365-200605030-00004

http://dx.doi.org/10.2165/00148365-200605040-00009


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875


http://dx.doi.org/10.2165/00019053-200624002-00013

Getz KA. Spotting the 'new' managed site networks. *Applied Clinical Trials*. 2006;15(9):34-36
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=370345


http://dx.doi.org/10.1097/00001888-200608000-00006

http://dx.doi.org/10.1016/j.tibtech.2006.05.003


http://harpers.org/archive/2006/07/letters-766/

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=334568

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website http://csdd.tufts.edu/reports
Kaitin KI, editor. CRO contribution to drug development is substantial and growing globally. *Tufts Center for the Study of Drug Development Impact Report*. 2006 Jan/Feb;8(1)**


Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials*. 2006;15(1):38-40  


Getz KA. Have we pushed our PIs too far? *Applied Clinical Trials*. 2005;14(9):34-36  


[dx.doi.org/10.2307/3564071](http://dx.doi.org/10.2307/3564071)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 2512  DiMasi JA  Hansen RW  Grabowski HG.  Reply: setting the record straight on setting the record straight: response to the Light and Warburton rejoinder.  *Journal of Health Economics*. 2005 Sep;24(5):1049-53  


RS 2509  Reichert JM  Rosensweig CJ  Faden LB  Dewitz MC.  Monoclonal antibody successes in the clinic.  *Nature Biotechnology*. 2005;23(9):1073-8  
http://dx.doi.org/10.1038/nbt0905-1073


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=149965


http://appliedclinicaltrialsonline.findpharma.com/appliedclinicaltrials/article/articleDetail.jsp?id=166546


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2501  Kaitin KI, editor. Decline in drug approvals is driving industry, FDA to enhance efficiency. Tufts Center for the Study of Drug Development Impact Report. 2005 Jan/Feb;7(1)**


http://dx.doi.org/10.1017/S0266462304001291

RS 2423  Milne C-P. Harbingers, or harvesters of change? European Pharmaceutical Review Supplement (Outsourcing). 2004 Winter:12-17


RS 2421  Cohen JP Paquette C Cairns CP. Switching prescription drugs to over the counter. BMJ. 2005 Jan 1;330(7481):39-41
http://dx.doi.org/10.1136/bmj.330.7481.39


http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=12516


**This publication is for sale at our website  http://cddd.tufts.edu/reports**


http://dx.doi.org/10.1038/nbt1204-1513


http://dx.doi.org/10.1177/009286150403800301


http://dx.doi.org/10.1056/NEJM200405203502127


http://dx.doi.org/10.1177/009286150303700401


http://dx.doi.org/10.1038/nrd1386


**This publication is for sale at our website  **http://csdd.tufts.edu/reports**

http://dx.doi.org/10.1177/009286150403800105


http://dx.doi.org/10.1016/S1359-6446(04)03025-9


http://dx.doi.org/10.1177/009286150303700403

http://dx.doi.org/10.1076/jmep.28.3.327.14586

http://dx.doi.org/10.1177/009286150303700310

http://dx.doi.org/10.1345/aph.1D110

http://dx.doi.org/10.1097/00045391-200309000-00010

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 2308 Kaitin KI, editor. CROs provide gateway to worldwide clinical trial recruitment efforts. Tufts Center for the Study of Drug Development Impact Report. 2003 Jul/Aug;5(4)**


**This publication is for sale at our website http://csdd.tufts.edu/reports**

[http://dx.doi.org/10.1016/S0167-6296(02)00126-1](http://dx.doi.org/10.1016/S0167-6296(02)00126-1)

RS 2301  Kaitin KI, editor. Increased pressure on drug industry is leading to greater focus on Japan. *Tufts Center for the Study of Drug Development Impact Report*. 2003 Jan/Feb;5(1)**


[http://dx.doi.org/10.2165/00019053-200220003-00011](http://dx.doi.org/10.2165/00019053-200220003-00011)


RS 2218  Kaitin KI, editor. Approval times for new drugs fell by more than a year during PDUFA. *Tufts Center for the Study of Drug Development Impact Report*. 2002 Nov/Dec;4(6)**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1038/nbt0802-780


http://dx.doi.org/10.1038/nbt0702-659

RS 2211  Cohen J  Chee J. Pharmacy benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care. Disease Management & Health Outcomes. 2002;10(4):221-7
http://dx.doi.org/10.1177/009286150103500228


**This publication is for sale at our website  http://csdd.tufts.edu/reports


RS 2203  Reichert JM Therapeutic monoclonal antibodies: trends in development and approval in the US. *Current Opinion in Molecular Therapeutics.* 2002;4(2):110-8


RS 2123  Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) *La Vanguardia* (Barcelona). 2001 18 Mar*


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1038/nbt0901-819

http://dx.doi.org/10.2165/00019053-200119070-00004


http://dx.doi.org/10.1177/009286150103500228


http://dx.doi.org/10.1177/009286150103500203


http://dx.doi.org/10.1067/mcp.2001.115446

http://dx.doi.org/10.1067/mcp.2001.115132


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

[http://dx.doi.org/10.1177/009286150103500108](http://dx.doi.org/10.1177/009286150103500108)

[http://dx.doi.org/10.1177/009286150103500109](http://dx.doi.org/10.1177/009286150103500109)


RS 2102  Kaitin KI, editor. FDA’s fast track program results in 62% approval rate after first 3 years. *Tufts Center for the Study of Drug Development Impact Report*. 2001 Jan/Feb;3(1)**

[http://dx.doi.org/10.1016/S0939-6411(00)00131-4](http://dx.doi.org/10.1016/S0939-6411(00)00131-4)


[http://dx.doi.org/10.1177/009286150003400425](http://dx.doi.org/10.1177/009286150003400425)

RS 2103  Cross-functional team focus on marketing is key to project success. *Tufts Center for the Study of Drug Development Impact Report*. 2000 Dec;2(9)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
| RS 2018 | Kaitin KI. Don’t turn back the clock on drug regulatory reform. *Tufts Center for the Study of Drug Development Impact Editorial*. 2000 Sep;2(7) [http://dx.doi.org/10.1097/01.COT.0000293239.37468.b0](http://dx.doi.org/10.1097/01.COT.0000293239.37468.b0) |

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 2008  Drug firms embrace pediatric study program during first 2 years of FDAMA.  *Tufts Center for the Study of Drug Development Impact Report*. 2000 Apr;2(3)

http://dx.doi.org/10.1001/jama.283.15.2013


http://dx.doi.org/10.1177/009286150003400129


http://dx.doi.org/10.1177/009286150003400101


http://dx.doi.org/10.1177/009286159903300401

**This publication is for sale at our website**  http://csdd.tufts.edu/reports


RS 9912  Planning, independence, feedback keep global R&D projects on track. *Tufts Center for the Study of Drug Development Impact Report*. 1999 Sep;1(3)


http://dx.doi.org/10.1097/00045391-199909000-00006


http://dx.doi.org/10.1016/S0149-2918(98)80010-6

RS 9903  Lasagna L. Rx: a heftier share for prescription drugs; giving medicine more of the health care pie could cut costs and aid patients. *Boston Globe*. 1998 Nov; 29:D2

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1126/science.282.5392.1263

http://dx.doi.org/10.1177/00928615980320S103


RS 9810  Lasagna L.  Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine.  Journal of Clinical Pharmacology. 1998;38:570-1, 575-6  
http://dx.doi.org/10.1002/j.1552-4604.1998.tb04460.x


http://dx.doi.org/10.1056/NEJM199804233381722


**This publication is for sale at our website  http://csdd.tufts.edu/reports**


**This publication is for sale at our website  http://csdd.tufts.edu/reports**

[http://dx.doi.org/10.3109/10601339709019438](http://dx.doi.org/10.3109/10601339709019438)


[http://dx.doi.org/10.1097/00045391-199705000-00002](http://dx.doi.org/10.1097/00045391-199705000-00002)


[http://dx.doi.org/10.1097/00045391-199701000-00010](http://dx.doi.org/10.1097/00045391-199701000-00010)

[http://dx.doi.org/10.1038/nbt0297-130](http://dx.doi.org/10.1038/nbt0297-130)

RS 9715  Kaitin KI. FDA reform: setting the stage for efforts to reform the agency. *Drug Information Journal*. 1997;31(1):27-33  
[http://dx.doi.org/10.1177/009286159703100105](http://dx.doi.org/10.1177/009286159703100105)

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 9714  Lasagna L  DiMasi JA.  Let’s speed up the approval of new indications for old drugs.  *Medical Marketing & Media* 1996;31(12):88-9

http://dx.doi.org/10.1016/S0009-9236(96)90209-X

http://dx.doi.org/10.1177/009286159603000416

RS 9625  DiMasi JA.  *Written testimony.*  House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives.  September 12, 1996


RS 9623  Kaitin KI.  *Statement.*  Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives.  The Need for FDA Reform, February 27, 1996.  104th Congress 2d Session:81-7, 100-1


http://archive.wilsonquarterly.com/essays/research-dilemma


RS 9618  Welling PG  Lasagna L  Banakar UV, editors.  *The drug development process.*  New York; Marcel Dekker:1996*

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1177/00928615960300103


http://dx.doi.org/10.1097/00045391-199609000-00008


http://dx.doi.org/10.1177/009286159603000201

**This publication is for sale at our website  http://csdd.tufts.edu/reports**


RS 9506  Shulman SR  Seibring M  Manocchia M.  *Letter to Hon. Judd Gregg, U.S. Senate.*  Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


PS 9596  Brown JS  DiMasi JA  Gosse ME  Manocchia M  Kaitin KI  Shulman SR.  *Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider.*  For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995


RS 9594  Bloom BR.  The United States needs a national vaccine authority.  *Science.* 1994 Sep 2;265(5177):1378-80

**This publication is for sale at our website   [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


http://dx.doi.org/10.1006/rtph.1994.1021

http://dx.doi.org/10.1038/clpt.1994.78

RS 9485  Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News.* 1993 Nov;(8)

http://dx.doi.org/10.1177/009286159302700306

http://dx.doi.org/10.1002/j.1552-4604.1994.tb03975.x

http://dx.doi.org/10.2165/00019053-19930301-00001

**This publication is for sale at our website**  http://csdd.tufts.edu/reports
<table>
<thead>
<tr>
<th>Reference</th>
<th>Author(s)</th>
<th>Title</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>RS 9376</td>
<td>Bienz-Tadmor B</td>
<td>Biopharmaceuticals go to market: patterns of worldwide development</td>
<td><em>Bio/Technology</em>. 1993;11(2):168-72 <a href="http://dx.doi.org/10.1038/nbt0293-168">http://dx.doi.org/10.1038/nbt0293-168</a></td>
</tr>
<tr>
<td>RS 9274</td>
<td>Shulman SR, Raiford DS</td>
<td>Promotional elements in educational programs: FDA attempts to wipe the slate clean</td>
<td><em>P&amp;T</em>. 1992;17:661-73*</td>
</tr>
</tbody>
</table>

**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 9266  Scoville B. Shifting the burden: restructuring the drug review process. Journal of Clinical Pharmacology and Therapeutics. 1991;49(3):229-33 http://dx.doi.org/10.1038/clpt.1991.21


**This publication is for sale at our website  http://csdd.tufts.edu/reports**
http://dx.doi.org/10.1038/clpt.1991.172

http://dx.doi.org/10.1056/NEJM199108013250513


RS 9162  Inman WHW.  Drug Safety Research Unit, University of Southampton.  *PEM News.* 1991 Aug;(7)

http://dx.doi.org/10.1016/0167-6296(91)90001-4


http://dx.doi.org/10.1002/j.1552-4604.1991.tb04963.x


http://dx.doi.org/10.1002/j.1552-4604.1991.tb03694.x

http://dx.doi.org/10.1002/sim.4780090302

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Shulman SR. La legislazione sulla responsabilità di produzione. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:27-8

Lasagna L. Le attività del Centro per lo Studio dello Sviluppo dei Farmaci. *Informazioni Stampa Interesse Sanitario* (Rome) 1990 Apr 9;#15:26

Inman WHW. Drug Safety Research Unit, University of Southampton, *PEM News*. 1988 Sep(5)


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


[http://dx.doi.org/10.2105/AJPH.79.11.1565](http://dx.doi.org/10.2105/AJPH.79.11.1565)

[http://dx.doi.org/10.1177/009286158802200104](http://dx.doi.org/10.1177/009286158802200104)


[http://dx.doi.org/10.1038/clpt.1989.118](http://dx.doi.org/10.1038/clpt.1989.118)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


RS 8934  Grabowski HG.  Medicaid patients' access to new drugs.  *Health Affairs* 1989;7:102-14  http://dx.doi.org/10.1377/hlthaff.7.5.102


RS 8930  Inman WHW.  Drug Safety Research Unit, University of Southampton.  *PEM News.* 1988 Sep;(5)


RS 8830  Shulman SR.  Drug refusal policy must include legal definition of competence.  *Hospital Formulary.* 1988 Jan;23:79

**This publication is for sale at our website  http://csdd.tufts.edu/reports**
| RS 8829 | DiMasi JA. The notion of "acceptable risk": comment. *Journal of Clinical Epidemiology*. 1988;41(9):939-41. [http://dx.doi.org/10.1016/0895-4356(88)90111-4](http://dx.doi.org/10.1016/0895-4356(88)90111-4) |
| RS 8824 | Wittes RE. Antineoplastic agents and FDA regulations: square pegs for round holes? *Cancer Treatment Reports*. 1987;71(9):795-806 |
| RS 8818 | Roberts EB Hauptman O. The financing threshold effect on success and failure of biomedical and pharmaceutical start-ups. *Management Science*. 1987;33(3):381-94. [http://dx.doi.org/10.1287/mnsc.33.3.381](http://dx.doi.org/10.1287/mnsc.33.3.381) |

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)
RS 8710 Inman WHW. Drug Safety Research Unit, University of Southampton, PEM News. 1987 Mar;(4)


RS 8705 Kaitin KI. Impact of generic drugs on the pharmaceutical marketplace. Private Practice. 1986 Sep;18:18-20 (Originally appeared as "Generic firms shun research, share rewards.")


**This publication is for sale at our website** http://csdd.tufts.edu/reports


[http://dx.doi.org/10.1017/S0266462300003445](http://dx.doi.org/10.1017/S0266462300003445)


[http://dx.doi.org/10.1080/00031305.1985.10479435](http://dx.doi.org/10.1080/00031305.1985.10479435)


RS 8600  Berry CL.  Unprovable verities.  *Human Toxicology.* 1985;5(3):159-60

RS 8699  Weintraub M Northington F.  Drugs that wouldn't die.  *Journal of the American Medical Association.*  1986 May 2;255(17):2327-8  
[http://dx.doi.org/10.1001/jama.1986.03370170091042](http://dx.doi.org/10.1001/jama.1986.03370170091042)

[http://dx.doi.org/10.1177/009286158602000105](http://dx.doi.org/10.1177/009286158602000105)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News*. 1985 Dec;(3)


Walker SR Schultz E Schuppan D Gelzer J. A comparative retrospective analysis of data for short- and long-term animal toxicity studies on 40 pharmaceutical compounds. *Archives of Toxicology*. 1984; Suppl 7:485-7


Mattison N. Sources of change affecting the U.S. pharmaceutical industry in the 1980s. *Pharmaceutical Medicine*. 1985;1:89-96*


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1016/0273-2300(85)90036-4


http://dx.doi.org/10.1016/j.1552-4604.1985.tb02819.x

http://dx.doi.org/10.1038/clpt.1985.54

http://dx.doi.org/10.1002/ddr.430040402


http://dx.doi.org/10.1038/clpt.1984.224


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 8478 Lasagna L. *Impediments to Vaccine Research, Medicine in the Public Interest Conference, Jan 9-10, 1984.* Boston: MIPI;1984

RS 8477 Inman WHW. Drug Surveillance Research Unit, University of Southampton, *PEM News.* 1984 Aug;(2)


RS 8474 Weintraub M. P&T committees and drug regulation in Norway: lessons to be learned. *Hospital Formulary.* 1984;19:347


RS 8468 Hutt PB. The importance of patent term restoration to pharmaceutical innovation: will extending patent life increase drug innovation? A search for answers. *Health Affairs.* 1982;1(2):5-24

**This publication is for sale at our website** [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)


RS 8367  Superior Court of New Jersey, Appellate Division.  Carol Ann Feldman, an infant, by her parent and guardian *ad litem* Harold Feldman, Plaintiffs - Appellants vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983

RS 8366  Inman WHW.  Drug Surveillance Research Unit, University of Southampton.  *PEM News*. 1983 Aug;(1)

RS 8365  Covington TR.  Toward a rational approach to the issue of prescribing authority for pharmacists.  *Drug Intelligence and Clinical Pharmacy*. 1983;17(9):660-6

[http://dx.doi.org/10.1038/clpt.1983.95](http://dx.doi.org/10.1038/clpt.1983.95)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

http://dx.doi.org/10.1038/clpt.1983.73

http://dx.doi.org/10.1038/clpt.1982.181

http://dx.doi.org/10.1136/bmj.283.6289.477

http://dx.doi.org/10.1111/j.1365-2125.1981.tb01251.x


http://dx.doi.org/10.1007/BF00396431

http://dx.doi.org/10.1007/BF00332351

http://dx.doi.org/10.1016/S0272-0590(82)80089-4

RS 8357b  Mahler H. Essential drugs for all. *Papers presented at the Eleventh IFPMA Assembly, Washington DC, Jun 7-8, 1982:* 64-70


RS 8262  Wardell WM. Is pharmaceutical innovation declining? *Pharmaceutical Technology.* 1982 Sep


RS 8260  Wardell WM  Mattison N. The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis. In: *WMA Follow-up Committee on Development and Allocation of Medical Care Resources.* Tokyo: Japan Medical Association;1982;84-98*


http://dx.doi.org/10.1002/j.1552-4604.1982.tb02664.x

***This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)***

RS 8253b  Schweiker RS. Remarks by the Honorable Richard S. Schweiker to the National Pharmaceutical Council Symposium. June 23, 1982


http://dx.doi.org/10.1038/clpt.1982.34

RS 8250  Wardell WM. *A statement on pharmaceutical patent life and innovation.* Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982


http://dx.doi.org/10.1001/jama.1981.03310450044021


RS 8153  Wardell WM  Velo GP, editors. *Drug development, regulatory assessment, and postmarketing surveillance.* NATO Advanced Institutes Series, 39 (Series A: Life Sciences) New York: Plenum; 1981*

http://dx.doi.org/10.1007/978-1-4684-4055-3

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


Sleep and the golden mean.  *The Sciences* 1980 Nov;  
The writing on the wall.  *The Sciences* 1979 Oct;  

[http://dx.doi.org/10.1016/0010-7824(81)90025-1](http://dx.doi.org/10.1016/0010-7824(81)90025-1)


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1056/NEJM197912273012602


http://dx.doi.org/10.1056/NEJM197907053010110


Hansen RW. Effects of incremental costs on pharmaceutical innovation. (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

Hansen RW. *The cost of regulation in the pharmaceutical industry: economic implications of three recent studies.* (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

Wardell WM. Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources. In: *Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources.* Tokyo: Japan Medical Association, 1980:139-50*

Wardell WM. Drug therapy (a response to questions on specific aspects of drug regulation). *Private Practice.* 1980 Oct:24-31*


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1002/j.1552-4604.1980.tb01660.x

RS 8051  Lasagna L. Pharmacology's labs have moved faster than the regulators. *Medical Tribune*. 1980 May 7;21:17


http://dx.doi.org/10.7326/0003-4819-92-3-419


RS 8046  Hansen RW. *Pharmaceutical development costs by therapeutic categories*. (Working Paper Series No. GPB-80-6) Rochester, NY: Graduate School of Management, University of Rochester; Mar 1980*


**This publication is for sale at our website [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
http://dx.doi.org/10.1007/BF01968667


http://dx.doi.org/10.1038/clpt.1980.160


PS 8032  Merrill RA. *Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials.* Rochester, NY: Center for the Study of Drug Development; Apr 1980


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**


http://dx.doi.org/10.1021/bk-1979-0109.ch009


http://dx.doi.org/10.1111/j.1365-2710.1979.tb00152.x

**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**
RS 7939  Lasagna L. Toxicological barriers to providing better drugs. *Archives of Toxicology*. 1979;43(1):27-33
http://dx.doi.org/10.1007/BF00695871


http://dx.doi.org/10.1002/j.1552-4604.1979.tb02464.x

http://dx.doi.org/10.1002/j.1552-4604.1979.tb01649.x


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**

RS 7927  Wardell WM. Rx: more regulation or better therapies. Regulation. 1979 Sep/Oct;3(5):25-33

RS 7926b Lasagna L. The diseases and drug needs of the Third World. Journal of Chronic Diseases. 1979;32(6):413-4  
http://dx.doi.org/10.1016/0021-9681(79)90101-2


http://dx.doi.org/10.1001/jama.1978.03280450060031

http://dx.doi.org/10.1126/science.644328

**This publication is for sale at our website  http://csdd.tufts.edu/reports**

[http://dx.doi.org/10.1007/BF01968666](http://dx.doi.org/10.1007/BF01968666)


[http://dx.doi.org/10.1001/jama.1978.03280460072023](http://dx.doi.org/10.1001/jama.1978.03280460072023)


PS 7816  Landau RL.  *What you should know about estrogens, or the perils of Pauline*. Rochester, NY: Center for the Study of Drug Development; Jun 1978

***This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)***


**This publication is for sale at our website http://csdd.tufts.edu/reports**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports]**


**This publication is for sale at our website  [http://csdd.tufts.edu/reports](http://csdd.tufts.edu/reports)**